Presentation Material for FY2027/3 First Half Business Results
Filed with TSE · · 24 pages · English
Summary by 6ix AI
Perseus Proteomics, Inc. has released its presentation material for the first half of its fiscal year, detailing business results and strategic developments. Financial results indicate a decline in net sales and an expanded net loss compared to the previous year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Perseus Proteomics, Inc. on 6ix
In the deck
Earlier from Perseus Proteomics
- Notice Regarding the Recognition of Non-operating Income, Non-operating Expenses, and Extraordinary Losses
- Non-consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)
- Non-consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)
- Notice Regarding the Results of a Clinical Study in Patients Who Participated in the Phase I Clinical Trial of PPMX-T003 for Polycythemia Vera
- (Amendments) Amendments to “Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2026”
Follow Perseus Proteomics into a list and get an email when it puts out news.
Follow Perseus Proteomics